Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6404069 | 1.00 | CYP1A2 (0.38) | CYP1A2TRPV1KMT2ARAB9APDE10A | |
| SCHEMBL6609609 | 0.92 | CYP1A2 (0.39) | CYP1A2TRPV1KMT2ARAB9APDE10A | |
| SCHEMBL6609601 | 0.92 | CYP1A2 (0.39) | CYP1A2TRPV1KMT2ARAB9APDE10A | |
| SCHEMBL6607764 | 0.88 | MMP2 (0.38) | CYP1A2KMT2ARAB9APDE10AKDM4E | |
| SCHEMBL6607771 | 0.88 | MMP2 (0.38) | CYP1A2KMT2ARAB9APDE10AKDM4E | |
| SCHEMBL6403781 | 0.87 | CYP1A2 (0.36) | CYP1A2TRPV1KMT2ARAB9APDE10A | |
| SCHEMBL6400334 | 0.87 | CYP1A2 (0.38) | CYP1A2KMT2ARAB9APDE10AKDM4E | |
| SCHEMBL6400327 | 0.87 | CYP1A2 (0.38) | CYP1A2KMT2ARAB9APDE10AKDM4E | |
| SCHEMBL6403783 | 0.86 | MMP2 (0.34) | CYP1A2TRPV1KMT2ARAB9APDE10A | |
| Hydrochloric Acid SCHEMBL6399825 | 0.85 | CYP1A2 (0.37) | CYP1A2TRPV1KMT2ARAB9APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999732-B2 | P2X3 receptor antagonists | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2024-06-04 | — | — | US | disclosed |
| US-20210246139-A1 | P2X3 RECEPTOR ANTAGONISTS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2021-08-12 | — | — | US | disclosed |
| CN-112584898-A | P2X3Receptor antagonists | 瑞蔻达蒂化学和制药工业股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| US-10844459-B2 | Process for extracting and recovering tantalum present in an acid aqueous phase by means of an ionic liquid, and use of such an ionic liquid for extracting the tantalum from an acid aqueous phase | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-11-24 | — | — | US | disclosed |
| EP-3334846-B1 | PROCESSES FOR EXTRACTING AND RECOVERING TANTALUM PRESENT IN AN ACID AQUEOUS PHASE BY MEANS OF AN IONIC LIQUID, AND USE OF SUCH AN IONIC LIQUID FOR EXTRACTING THE TANTALUM FROM AN ACID AQUEOUS PHASE | CENTRE NAT RECH SCIENT (FR) | 2020-10-14 | — | — | EP | disclosed |
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | SMITHKLINE BEECHAM PLC | 2005-12-29 | — | — | US | disclosed |
| EP-1289980-B1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | disclosed |
| EP-1289980-A1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001090100-A1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246139-A1 | P2X3 RECEPTOR ANTAGONISTS | P2RX3, P2RX5, P2RX2 | CYP1A2 1123/4885TRPV1 12/4885KMT2A 4283/4885 |
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | CD22, CD2, NEU3 | CYP1A2 1075/4885TRPV1 1431/4885KMT2A 2661/4885 |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | CD22, CD2, NEU3 | CYP1A2 909/4885TRPV1 1857/4885KMT2A 2906/4885 |
| US-11999732-B2 | P2X3 receptor antagonists | P2RX3, P2RX5, P2RX2 | CYP1A2 1123/4885TRPV1 12/4885KMT2A 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.